If inhibition of PTP1B renders these cells more vulnerable for induction of cell death, this could open up possibilities of using PTP1B inhibitors in therapy against a subset of breast cancer tumors, namely those enriched with cells showing an EMT phenotype. Here, PTPN1 is linked to breast carcinoma.